Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018206 · ClinicalTrials.gov registry record · Phase 4
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis
A Phase 4 study, sponsored by Care Arthritis.
- Not yet
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT07018206 is a Phase 4 study that has not yet begun recruiting, run by Care Arthritis. The registered enrollment target is 200 participants.
The verdict
NCT07018206, a Phase 4 study, has not yet begun recruiting, sponsored by Care Arthritis.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a Phase IV, open-label, multicenter study evaluating the impact of upadacitinib on the frequency of acute anterior uveitis (AAU) in adults with axial spondyloarthritis (axSpA) and a documented history of AAU in the prior 52 weeks. Approximately 200 participants will be enrolled across North America and Europe, including both biologic DMARD-inadequate responders (bDMARD-IR) and bDMARD-naïve patients. The primary objective is to assess the change in exposure-adjusted AAU event rate during 52 weeks of treatment with upadacitinib 15 mg once daily. Secondary objectives include evaluating the effect of upadacitinib on disease activity, pain, physical function, quality of life, and sleep. Safety and tolerability will also be assessed throughout the study.
Interventions
- DRUG Upadacitinib 15 MG [Rinvoq]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07018206
The ClinicalTrials.gov registry entry for NCT07018206 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Care Arthritis, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Upadacitinib 15 MG [Rinvoq] is the first listed.
NCT07018206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07018206 about?
NCT07018206 is a clinical study titled "Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis". This is a Phase IV, open-label, multicenter study evaluating the impact of upadacitinib on the frequency of acute anterior uveitis (AAU) in adults with axial spondyloarthritis (axSpA) and a documented history of AAU in the prior 52 weeks. Approximately 200 participants will be enrolled across North ...
What is the current status of trial NCT07018206?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2026-05. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07018206?
The interventions under investigation include: Upadacitinib 15 MG [Rinvoq] (DRUG).
Who is sponsoring clinical trial NCT07018206?
This trial is sponsored by Care Arthritis, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.